Nimmerjahn F - Search Results

1

Editorial: Effector functions of therapeutic antibodies.

Boross P, Peipp M, Nimmerjahn F. Boross P, et al. Among authors: nimmerjahn f. Front Immunol. 2023 Jan 12;13:1126966. doi: 10.3389/fimmu.2022.1126966. eCollection 2022. Front Immunol. 2023. PMID: 36713416 Free PMC article. No abstract available.

2

Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV.

Otten MA, van der Bij GJ, Verbeek SJ, Nimmerjahn F, Ravetch JV, Beelen RH, van de Winkel JG, van Egmond M. Otten MA, et al. Among authors: nimmerjahn f. J Immunol. 2008 Nov 15;181(10):6829-36. doi: 10.4049/jimmunol.181.10.6829. J Immunol. 2008. PMID: 18981101

3

Low level of FcγRIII expression on murine natural killer cells.

Biburger M, Nimmerjahn F. Biburger M, et al. Among authors: nimmerjahn f. Immunol Lett. 2012 Mar 30;143(1):53-9. doi: 10.1016/j.imlet.2012.01.002. Epub 2012 Jan 21. Immunol Lett. 2012. PMID: 22285694

4

FcγRIIB: a modulator of cell activation and humoral tolerance.

Lehmann B, Schwab I, Böhm S, Lux A, Biburger M, Nimmerjahn F. Lehmann B, et al. Among authors: nimmerjahn f. Expert Rev Clin Immunol. 2012 Mar;8(3):243-54. doi: 10.1586/eci.12.5. Expert Rev Clin Immunol. 2012. PMID: 22390489 Review.

5

The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.

Glorius P, Baerenwaldt A, Kellner C, Staudinger M, Dechant M, Stauch M, Beurskens FJ, Parren PW, Winkel JG, Valerius T, Humpe A, Repp R, Gramatzki M, Nimmerjahn F, Peipp M. Glorius P, et al. Among authors: nimmerjahn f. Leukemia. 2013 Jan;27(1):190-201. doi: 10.1038/leu.2012.150. Epub 2012 Jun 4. Leukemia. 2013. PMID: 22660187

6

Of mice and men: the need for humanized mouse models to study human IgG activity in vivo.

Lux A, Nimmerjahn F. Lux A, et al. Among authors: nimmerjahn f. J Clin Immunol. 2013 Jan;33 Suppl 1:S4-8. doi: 10.1007/s10875-012-9782-0. Epub 2012 Sep 5. J Clin Immunol. 2013. PMID: 22948744 Review.

7

Impact of immune complex size and glycosylation on IgG binding to human FcγRs.

Lux A, Yu X, Scanlan CN, Nimmerjahn F. Lux A, et al. Among authors: nimmerjahn f. J Immunol. 2013 Apr 15;190(8):4315-23. doi: 10.4049/jimmunol.1200501. Epub 2013 Mar 18. J Immunol. 2013. PMID: 23509345

8

Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo.

Schwab I, Mihai S, Seeling M, Kasperkiewicz M, Ludwig RJ, Nimmerjahn F. Schwab I, et al. Among authors: nimmerjahn f. Eur J Immunol. 2014 May;44(5):1444-53. doi: 10.1002/eji.201344230. Epub 2014 Mar 7. Eur J Immunol. 2014. PMID: 24505033 Free article.

9

FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities.

Nimmerjahn F, Gordan S, Lux A. Nimmerjahn F, et al. Trends Immunol. 2015 Jun;36(6):325-36. doi: 10.1016/j.it.2015.04.005. Epub 2015 May 13. Trends Immunol. 2015. PMID: 25981969 Review.

10

Three blocks are not enough--Blocking of the murine IgG receptor FcγRIV is crucial for proper characterization of cells by FACS analysis.

Biburger M, Trenkwald I, Nimmerjahn F. Biburger M, et al. Among authors: nimmerjahn f. Eur J Immunol. 2015 Sep;45(9):2694-7. doi: 10.1002/eji.201545463. Epub 2015 Jul 21. Eur J Immunol. 2015. PMID: 26138319 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

227 results

Search Page

Filters